Related Experiment Video
Updated: Mar 9, 2026
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer
Francesco Pasqualetti1, Sabrina Montrone2, Caterina Vivaldi3
1Department of Clinical and Translational Sciences, Division of Radiation Oncology, University of Pisa, Pisa, Italy f.pasqualetti@ao-pisa.toscana.it francep24@hotmail.com.
Aim:
To assess the role of stereotactic body radiotherapy (SBRT) in pulmonary metastases from colorectal cancer (CRC).
Patients And Methods:
Thirty-three consecutive patients with pulmonary metastases from CRC who received SBRT were included in the analysis. The primary endpoints were local and systemic progression-free survival, a secondary endpoint was the safety profile of SBRT.
Results:
A total of 56 lesions were treated with SBRT. A single nodule was treated in 15 patients, two in 13 and three in five. The radiotherapy dose and the adopted fractionations were 24-27 Gy as a single fraction for 40 lesions and 27-42 Gy in three fractions (2-3 times a week) for the other 16 lesions. After a median follow-up of 22.8 months (range=1.3-45.7 months), the median progression-free survival of the irradiated sites was 13.4 months.
Conclusion:
SBRT can be considered as local therapy in patients with lung metastases from CRC.
